Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers

NCT04447781 is registered in ClinicalTrials.gov with International Vaccine Institute as lead sponsor.

NCT NCT04447781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04447781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers
Lead sponsor
International Vaccine Institute
Phase
Phase 1/2
Overall status
Completed
Start date
July 15, 2020
Completion date
May 25, 2022
Enrollment
79 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infection, sars-cov 2